期刊
SLAS DISCOVERY
卷 25, 期 10, 页码 1141-1151出版社
ELSEVIER SCIENCE INC
DOI: 10.1177/2472555220942123
关键词
SARS-CoV-2; COVID-19; coronavirus infection; RNA-dependent RNA polymerase; RdRP assays; RdRP inhibitors
资金
- Intramural Research Programs of the National Center for Advancing Translational Sciences, National Institutes of Health
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [ZIATR000018, ZIATR000422] Funding Source: NIH RePORTER
COVID-19 respiratory disease caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has rapidly become a global health issue since it emerged in December 2019. While great global efforts are underway to develop vaccines and to discover or repurpose therapeutic agents for this disease, as of this writing only the nucleoside drug remdesivir has been approved under Emergency Use Authorization to treat COVID-19. The RNA-dependent RNA polymerase (RdRP), a viral enzyme for viral RNA replication in host cells, is one of the most intriguing and promising drug targets for SARS-CoV-2 drug development. Because RdRP is a viral enzyme with no host cell homologs, selective SARS-CoV-2 RdRP inhibitors can be developed that have improved potency and fewer off-target effects against human host proteins and thus are safer and more effective therapeutics for treating COVID-19. This review focuses on biochemical enzyme and cell-based assays for RdRPs that could be used in high-throughput screening to discover new and repurposed drugs against SARS-CoV-2.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据